Immunosuppressive minimization with mTOR inhibitors and belatacept

Publisher： John Wiley & Sons Inc

E-ISSN： 1432-2277|28|8|921-927

ISSN： 0934-0874

Source： TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol.28, Iss.8, 2015-08, pp. : 921-927

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR inhibitors in renal cell carcinoma

By Battelli Chiara   Cho Daniel C  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 359-367

Future Medicine

Access to resources Recommend Favorite

Clinical Development of mTOR Inhibitors: A Focus on Lymphoma

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 103-110

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR

By Marin Philippe   Meffre Julie   Bockaert Joël  

Médecine/sciences, Vol. 29, Iss. 1, 2013-01 ,pp. : 28-30

Edp Sciences

Access to resources Recommend Favorite

Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy

By  

Oncology, Vol. 85, Iss. 1, 2013-06 ,pp. : 8-13

Karger

Access to resources Recommend Favorite

Bullous pemphigoid induced by m‐TOR inhibitors in renal transplant recipients

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 8, 2015-08 ,pp. : 1626-1630

John Wiley & Sons Inc

Access to resources Recommend Favorite